Design, synthesis and pharmacological evaluation of chalcone derivatives as acetylcholinesterase inhibitors. 2014

Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
College of Chemistry and Chemical Engineering, Hu'nan University, Changsha 410082, China. Electronic address: pharmaliu@126.com.

A novel series of chalcone derivatives (4a-8d) were designed, synthesized, and evaluated for the inhibition activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). The logP values of the compounds were shown to range from 1.49 to 2.19, which suggested that they were possible to pass blood brain barriers in vivo. The most promising compound 4a (IC50: 4.68 μmol/L) was 2-fold more potent than Rivastigmine against AChE (IC50: 10.54 μmol/L) and showed a high selectivity for AChE over BuChE (ratio: 4.35). Enzyme kinetic study suggested that the inhibition mechanism of compound 4a was a mixed-type inhibition. Meanwhile, the result of molecular docking showed its potent inhibition of AChE and high selectivity for AChE over BuChE.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D002091 Butyrylcholinesterase An aspect of cholinesterase (EC 3.1.1.8). Pseudocholinesterase,Benzoylcholinesterase,Butyrylthiocholinesterase
D002599 Chalcone An aromatic KETONE that forms the core molecule of CHALCONES. Benzalacetophenone,Benzylideneacetophenone,1,3-Diphenyl-2-Propen-1-One,Chalkone,1,3 Diphenyl 2 Propen 1 One
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014101 Torpedo A genus of the Torpedinidae family consisting of several species. Members of this family have powerful electric organs and are commonly called electric rays. Electric Rays,Torpedinidae,Rays, Electric
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
February 2009, European journal of medicinal chemistry,
Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
March 2009, European journal of medicinal chemistry,
Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
January 2015, Yao xue xue bao = Acta pharmaceutica Sinica,
Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
July 2008, Bioorganic & medicinal chemistry letters,
Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
June 2015, Yao xue xue bao = Acta pharmaceutica Sinica,
Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
January 2023, Journal of biomolecular structure & dynamics,
Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
May 2013, Die Pharmazie,
Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
October 2023, Bioorganic & medicinal chemistry letters,
Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
January 2018, Bioorganic & medicinal chemistry,
Hao-ran Liu, and Xian-jun Liu, and Hao-qun Fan, and Jing-jing Tang, and Xiao-hui Gao, and Wu-Kun Liu
March 2017, ChemMedChem,
Copied contents to your clipboard!